My research has been focused on enteric infections and vaccine development for these infections.
With regard to enteric infections, this has included laboratory detection of these agents, describing their epidemiology in travelers and developing country populations, developing appropriate clinical management strategies including antibiotics and rehydration methods.
With regard to vaccines, I have participated in the development of vaccines for cholera, rotavirus, enterotoxigenic E coli, shigellosis and other bacterial infections.
Most recently, i have initiated a large project called the DOVE project (Delivering Oral Cholera Vaccine Effectively). Working in collaboration with UNICEF, WHO and other partners, this project will facilitate the use oral cholera vaccine as part of an integrated strategy for cholera control.
Honors and Awards
Gates Award for Global Health for the ICDDRB
Independence Day Award for the ICDDRB
International Health, cholera, cholera vaccine, Cameroon, rotavirus, diarrhea, Bangladesh, Gates Award, enterotoxigenic Escherichia coli, shigella, International Center, epidemiology, oral rehyration solution, ORS, malaria, tuberculosis
Ruan X, Knudsen DE, Wollenberg KM, Sack DA, Zhang W. An adhesin multiepitope fusion antigen (MEFA) induces broadly protective antibodies that prevent adherence of Escherichia coli strains expressing CFA/I, CFA/II and CFA/IV. Clin Vaccine Immunol. 2013.
Qadri, F., Bhuiyan, T. R., Sack, D. A., and Svennerholm, A. M. (2013) Immune responses and protection in children in developing countries induced by oral vaccines, Vaccine31, 452-460.
Chakraborty S, Alam M, Scobie HM, Sack DA. Adaptation of a simple dipstick test for detection of Vibrio cholerae O1 and O139 in environmental water. Frontiers in microbiology. 2013; 4: 320
Sack, DA. A new era in the history of cholera: the road to elimination. International Journal of Epidemiology 2013;42:1537–1540.
Darsley MJ, Chakraborty S, Denearing B, Sack DA, Feller A, Buchwaldt C, et al.The Oral, Live Attenuated Enterotoxigenic Escherichia coli Vaccine ACE527 Reduces the Incidence and Severity of Diarrhea in a Human Challenge Model of Diarrheal Disease. Clinical and vaccine immunology : Clin Vaccine Immunol 2012; 19(12):1921-31